HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Guidelines for the use of intravenous immunoglobulin in the treatment of neurologic diseases.

Abstract
The use of intravenous immunoglobulin (IVIg) in the management of patients with neuroimmune disorders has shown a progressive trend over the last few years. Despite the wide use of IVIg, consensus on its optimal use is deficient. The European Federation of Neurological Societies (EFNS) guidance regulations offer consensus recommendations for optimal use of IVIg. The effectiveness of IVIg has been proven in Guillain-Barré syndrome (level A), chronic inflammatory demyelinating polyradiculoneuropathy (level A), multifocal mononeuropathy (level A), acute exacerbations of myasthenia gravis and short-term treatment of severe myasthenia gravis (level A). As a second-line treatment, the use of IVIg is recommended in dermatomyositis in combination with prednisone (level B) and is considered as a treatment option in polymyositis (level C). As a second- or even third-line therapy, the use of IVIg should be considered in patients with relapsing-remitting multiple sclerosis if conventional immunomodulatory therapies are not tolerated (level B) and in relapses during pregnancy or post-partum period (good clinical practice point). Finally, it appears that the use of IVIg has a beneficial effect also in stiff-person syndrome (level A), some paraneoplastic neuropathies (level B), and some acute-demyelinating diseases and childhood refractory epilepsy (good practice point).
AuthorsVanja Bascić-Kes, Petar Kes, Iris Zavoreo, Marijana Lisak, Lucija Zadro, Lejla Corić, Vida Demarin, Ad Hoc Comittee of the Croatian Society for Neurovascular Disorders, Croatian Medical Association
JournalActa clinica Croatica (Acta Clin Croat) Vol. 51 Issue 4 Pg. 673-83 (Dec 2012) ISSN: 0353-9466 [Print] Croatia
PMID23540178 (Publication Type: Journal Article, Practice Guideline)
Chemical References
  • Immunoglobulins, Intravenous
  • Immunologic Factors
Topics
  • Humans
  • Immunoglobulins, Intravenous (therapeutic use)
  • Immunologic Factors (therapeutic use)
  • Nervous System Diseases (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: